Summary
Updated Aug 30, 2026
Matthew Pratt Whalen is Director of Telomir Pharmaceuticals, Inc. (TELO). 4 SEC Form 4 filings on record going back to 2024, most recently on 27 July 2026.
Trading Pattern
InsiderAlpha's records for Matthew Pratt Whalen go back to 2024: 4 primary Form 4 filings, an average of 1.3 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who have reported open-market trades at the same companies as Matthew Pratt Whalen. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Erez Aminov - $134K of MIRA open-market activity on record
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Matthew Pratt Whalen?
Matthew Pratt Whalen is a corporate insider, tracked as Director of Telomir Pharmaceuticals, Inc. (TELO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew Pratt Whalen submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Matthew Pratt Whalen's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Matthew Pratt Whalen and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial